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choice for young patients (pts) with severe manifestations of the
disease. In this study, we analyze the results in 19 boys transplanted
in 2 BMT centers between 04/92–03/05. Age: 7 months to 14 years
(M: 2 years). All but one pt had the classical syndrome with many
serious infections (especially CMV related) or autoimmunity prior
to transplant.Stem cell source: Bone marrow from related: 9 pts or
cord blood (CB) from unrelated donors:10 pts. HLA disparities:
Bone marrow: 6/6: 7 pts and 5/6: 2 pts; CB: 6/6: 1 pt, 5/6: 6 pts and
4/6: 3 pts. Preparatory regimen: Busulfan(BU)  Cyclophospha-
mide(CY)  ATG: 17 pts; BU  Fludara: 1 pt, and BU  CY 
Thiotepa: 1 pt. GVHD prophylaxis:cyclosporine (csa)  metho-
trexate: 8 pts; csa  steroids: 10 pts, and csa  MMF: 1 pt. ATG
was added to pts receiving transplants from donors other than
HLA identical siblings. TNC infused: bone marrow 2, 3—10 
108/kg (M: 3, 08) and CB: 4, 9mdash;8,8–107/kg (6, 12).
Sixteen pts (84%) are alive between 117 to 3997 days (M: 776 days)
after SCT. All pts survived more than 28 days and were evaluable
for engraftment. Mucositis grade I-II occurred in most pts. VOD
(mild): 2 pts. Three pts died on day 34 (Unrelated CB 4/6,
pulmonary aspergilosis), day 65, and day 117 (HLA identical
siblingsmdash;CMV pneumonitis). Primary graft failure occurred
in 2 pts who received Unrelated 4/6 CB and only 1 pt is alive and
well on day 370 after the second CB infusion. This pt developed
acute (grade III) and chronic (extensive) GVHD and many other
severe viral infections. Seventeen pts engrafted and the median
time to reach ANC 	 500/ul was 22 days (10–30) and platelets 	
20.000/ul was 35 days (14–77). Acute GVHD occurred in 7/17 pts
(only one pt grade IV) and chronic GVHD in 3/16 pts (extensive
and severe). Three pts are still receiving treatment with immuno-
supressive drugs. Full donor chimerism was achieved in 15/16
surviving pts.Viral infections were frequent complications, espe-
cially in the URD cord blood transplants.We conclude that SCT in
pts with WAS has an excellent survival and should be indicated to
young pts with severe manifestations of the disease.
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Liver complications are one of the major causes of morbidity
and mortality following BMT. Determination of the factors of
liver injury leads to earlier diagnosis after BMT and improves
prognosis. We studied 113 major thalassemic patients who
have been transplanted from 1990–2000 in bone marrow trans-
plantation center of Shariati Hospital. Sixty-two were male and
51 were female. Twenty-seven patients were class 1, 56 were
class 2, and 30 were class 3. The median age of each class were
6.5, 6.3, and 8.7 year. Conditioning regimen consisted of busul-
fan (3.5–4 mg/Kg) and cyclophophamide (40–50 mg/Kg).For
GVHD prophylaxis we gave cyclosporine  metothoroxate.
Grade of liver ﬁbrosis was deﬁned by biopsy in all patients
before BMT. All patients and their donors tested for HBSAg,
HBSAb, HCVAb, and CMVAb with RIA method. We assessed
causes of liver dysfunction before and after transplantation and
effect of high ferritin level on liver function. Hepatic dysfunc-
tion in ﬁrst year after transplantation was seen in 86 (76%)
patients. Causes of liver dysfunction consisted of 53.1%
GVHD, 15.93% cyclosporine hepatotoxicity, 7.07% condition-
ing regimen hepatotoxicity, and VOD. In all three classes he-
patic GVHD, cyclosporine toxicity, death, and normal liver
function post BMT had signiﬁcant relation with hepatic dys-
function before BMT (P  .001). In patients with ferritin level
more than 1000, there was signiﬁcant hepatotoxicity with con-
ditioning regimen (P  .001). According to our study, hepatic
GVHD (%53.1) is the most common cause of hepatic dysfunc-
tion in all three classes.
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The patient was born June 1971. The diagnosis of SCID was
established at 3 months of age. Retrospective analysis revealed
JAK3 mutations compatible with autosomal recessive SCID. In
December 1971, he was treated with 3 infusions of BM aspirates,
totaling 7 107 nucleated cells from his mother’s brother, selected
because of a negative donor versus recipient MLR. Retrospective
HLA-typing revealed DRB1 and DQB1 identity but multiple class
I mismatches. No conditioning or GvHD prophylaxis was given. A
skin rash was observed 2 weeks after the ﬁrst infusion. No other
signs of GvHD occurred. The lymphocyte count was 5100 per mL
one year after transplantation, ca. 50% of the PBMC expressed the
not shared donor derived HLA class I antigens and 63% were
SRBC rosetting cells. Mitogen responses were normalized but
there was persistent absence of donor derived Rh(D) positive red
blood cells and of IgG and IgA production, whereas IgM isoag-
glutinin developed normally. Low blood T lymphocyte count was
noted in 1988. In 2000, the blood CD4 count was decreased to
200 per mL, and the CD8 count to 300 per mL. The TRECs
containing CD4 cell count was 0.02 per mL and the TRECs
containing CD8 cell count 0.03 per mL (1 to 2% of normal for
age). Bone marrow CD34 cells, peripheral blood neutrophils,
and B lymphocytes were of recipient origin, whereas the few
circulating T lymphocytes were of donor origin (microsatellite
analysis). A peripheral blood stem cell harvest was procured (De-
cember 2001) from the original donor and CD34 puriﬁed using
the CliniMACS device and the CliniMACS CD34 reagent set. The
patient received a total of 2.7  106 CD34 cells and 0.08  104
CD3 cells per kg BW. Cyclosporin was given for 3 month as
GvHD prophylaxis. No evidence of GvHD occurred. Subsequent
blood tests have shown no major change in the number of circu-
lating CD3, CD4 CD45RA, or CD8 CD45RA lymphocytes
over time. However, the number of CD4 and CD8 cells containing
TRECs increased within the 600 days after boosting to 1.5 and 2.5
per mL, respectively, (normal for recipient age). A subsequent
decline has been observed. We conclude that descendants from the
boosting donor CD34 cells were able to undergo maturation in
the thymus but a persistent take of donor derived CD34 cells was
not established.
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Background: Graft failure and GVHD remain major causes of
failure in HSCT for children with non-malignant disorders (MND).
Oral busulfan (BU), cyclophosphamide (CY), equine antithymocyte
globulin (ATG) is a standard preparative used for children with
NMD. We present preliminary data for a preparative regimen of
Bulsufex®, cyclophosphamide, and Thymoglobulin® (BU/CY/
Thymo). The regimen was developed for ease of administrtion, es-
pecially for young children, and theorectic reduction of GVHD sec-
ondary to more in vivo T cell depletion associated with
Thymoglobulin® compared to equine ATG.Methods:The regimen
included Busulfex® [0.8 mg/kg (	12 kg) or 1.1 mg/kg (12 kg)] q6
hour  16 (dose adjusted to target AUC  1125 M-minute). Cy-
clophosphamide (50 mg/kg/day  4), Thymoglobulin® (2.5 mg/kg/
day  4) with CSA and short course MTX (or methylpredisone for
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